Skip to main content

Clinical Trials Using Alpelisib

Review the clinical trials studying alpelisib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-12 of 12

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Status: Active
Location: 19 locations
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Status: Active
Location: 18 locations
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
Status: Active
Location: 6 locations
Fulvestrant and Neratinib, Alpelisib, Everolimus or Abemaciclib for the Treatment of Estrogen Receptor Positive HER2 Negative Metastatic or Locally Recurrent Breast Cancer Previously Treated with a CDK4/6 Inhibitor, GERTRUDE Trial
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Status: Active
Location: University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin
Alpelisib and Pembrolizumab for the Treatment of Patients with Locally Advanced, Unresectable, or Metastatic Melanoma or Triple Negative Breast Cancer, SELENA Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Status: Active
Location: See ClinicalTrials.gov
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tamoxifen and Alpelisib Compared to Fulvestrant and Zotatifin for the Treatment of Newly Diagnosed or Recurrent Estrogen Receptor Positive, HER2 Negative Breast Cancer
Status: Temporarily Closed to Accrual
Location: 2 locations
Evaluation of Circulating Tumor DNA Levels as a Predictive Marker for Switching Treatment Earlier in Patients with Metastatic Breast Cancer
Status: Temporarily Closed to Accrual
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Status: Active
Location: 451 locations
Implantable Microdevice for the Delivery of Drugs and their Effect on Tumors in Patients with Sarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas